Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00082589 · ClinicalTrials.gov registry record · Phase 4

The Purpose of This Study is to Determine if Eplerenone is Effective in Treatment of Mild to Moderate Heart Failure

A Phase 4 study of Heart Failure, Congestive, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.

Completed
Registry status
Phase 4
Development phase
250
Enrollment target
20
Study locations

NCT00082589: Completed Phase 4 study of Heart Failure, Congestive, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.

NCT00082589 is a Phase 4 study of Heart Failure, Congestive that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 250 participants, below the 669-participant average among 39 other Heart Failure, Congestive trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00082589, a Phase 4 study of Heart Failure, Congestive, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.

COMPLETED
Registry status
Phase 4
Development phase
250 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to determine if eplerenone is effective in the treatment of mild to moderate heart failure

Conditions Studied

Interventions

  • DRUG Eplerenone

Study Locations (20)

California

  • Pfizer Investigational Site - Castro Valley
  • Pfizer Investigational Site - San Diego
  • Pfizer Investigational Site - Santa Rosa
  • Pfizer Investigational Site - Walnut Creek

Florida

  • Pfizer Investigational Site - Fort Lauderdale
  • Pfizer Investigational Site - Jacksonville
  • Pfizer Investigational Site - Jacksonville

Georgia

  • Pfizer Investigational Site - Atlanta
  • Pfizer Investigational Site - Augusta
  • Pfizer Investigational Site - Covington

Illinois

  • Pfizer Investigational Site - Bloomington
  • Pfizer Investigational Site - Normal

Indiana

  • Pfizer Investigational Site - Indianapolis
  • Pfizer Investigational Site - Indianapolis

Michigan

  • Pfizer Investigational Site - Ann Arbor
  • Pfizer Investigational Site - Detroit

Colorado

  • Pfizer Investigational Site - Denver

Connecticut

  • Pfizer Investigational Site - New Haven

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2004-04
Est. Completion 2006-03
Phase Phase 4

What the finished NCT00082589 record still lists

NCT00082589 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, below the 669-participant average among 39 other Heart Failure, Congestive trials with a reported enrollment target (63% lower).

The record links to 1 condition, with Heart Failure, Congestive appearing as the primary indexed condition, and to 1 intervention - of which Eplerenone is the first listed.

NCT00082589 names 20 study sites across 10 states, led by California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT00082589 about?

NCT00082589 is a clinical study titled "The Purpose of This Study is to Determine if Eplerenone is Effective in Treatment of Mild to Moderate Heart Failure". The purpose of this study is to determine if eplerenone is effective in the treatment of mild to moderate heart failure

What is the current status of trial NCT00082589?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 250 participants. The study started on 2004-04. Estimated completion is 2006-03.

What conditions does trial NCT00082589 study?

This clinical trial studies the following conditions: Heart Failure, Congestive.

What interventions are being tested in trial NCT00082589?

The interventions under investigation include: Eplerenone (DRUG).

Who is sponsoring clinical trial NCT00082589?

This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00082589 being conducted?

This trial has 20 study locations across California, Colorado, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Failure, Congestive

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00082589's enrollment target sits among peer trials

250 17th of 39 higher than 23 of 39 other Heart Failure, Congestive trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Heart Failure, Congestive trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00483249 · 250 participants · NA

    Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm

  • NCT00777712 · 250 participants

    Mechanisms Underlying Impaired Diabetic Wound Healing

  • NCT01451502 · 250 participants · NA

    Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units

  • NCT01771718 · 250 participants

    Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00082589, the US trial registry maintained by the National Library of Medicine. NCT00082589 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.